Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study

Purpose We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Methods Observational, prospective, multicenter study performed by 6 hospital...

Descripción completa

Detalles Bibliográficos
Autores: Mangues Bafalluy, Irene, Bernárdez Jiménez, Beatriz, Martínez Sesmero, José Manuel, Navarro Ruiz, Andrés, Martín Conde, María Teresa, Rubio Salvador, Ana Rosa, Rius Perera, Judith, Gilabert Sotoca, Marta, Domínguez López, Marta, Callejo Mellén, Ángel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:dnet:idus________::3d7ab69d9e27e280a450acc1a7f098ca
Acceso en línea:https://hdl.handle.net/11441/186236
https://doi.org/10.1007/s00432-025-06264-0
Access Level:acceso abierto
Palabra clave:Non-small cell lung cáncer
Oral chemotherapy
Tyrosine kinase inhibitors
Anaplastic lymphoma kinase inhibitors
Adherence
Progression-free survival
id ES_bb0f327deb200b286bb3e66b73d7723c
oai_identifier_str oai:dnet:idus________::3d7ab69d9e27e280a450acc1a7f098ca
network_acronym_str ES
network_name_str España
repository_id_str
spelling Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective studyMangues Bafalluy, IreneBernárdez Jiménez, BeatrizMartínez Sesmero, José ManuelNavarro Ruiz, AndrésMartín Conde, María TeresaRubio Salvador, Ana RosaRius Perera, JudithGilabert Sotoca, MartaDomínguez López, MartaCallejo Mellén, ÁngelNon-small cell lung cáncerOral chemotherapyTyrosine kinase inhibitorsAnaplastic lymphoma kinase inhibitorsAdherenceProgression-free survivalPurpose We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Methods Observational, prospective, multicenter study performed by 6 hospital pharmacists in Spain. The primary outcome was the proportion of treatment adherence as evaluated by pill reconciliation during the 3-month active follow-up period. Those with an adherence > 80% were categorized as adherent. We performed multivariate Cox regression analyses to explore the factors associated with progression-free survival. Results From December 2019 to November 2022, we recruited 95 evaluable patients. Most of the patients received osimertinib (n = 45, 45.3%) or a first- or second-generation tyrosine kinase inhibitor (n = 23, 34.8%). Eighty-one patients showed greater than 80% adherence (85.3%, 95% CI 78.1% to 92.4%), as evaluated based on pill reconciliation; the mean (SD) adherence to OAT was 94.7% (11.4). According to the univariate analysis, the time to progression from study entry was significantly shorter among patients who were nonadherent than among those who were adherent (median 6.5 months vs. not reached, log-rank test p = 0.006; hazard ratio [HR] 2.619, 95% confidence interval [CI] 1.240–5.532). In the multivariate Cox regression analysis, nonadherence was the single factor associated with progression-free survival. Conclusion Consistent with previous evidence in this setting, our results suggest that adherence to oral antineoplastic treatment among patients with NSCLC is high. Whether this high rate of adherence translates to better clinical outcomes should be further evaluated in larger samples.SpringerLenguajes y Sistemas InformáticosTIC205: Ingeniería del Software Aplicada2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/186236https://doi.org/10.1007/s00432-025-06264-0reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésJournal of Cancer Research and Clinical Oncology, 151 (8), 224-9 p.. https://link.springer.com/article/10.1007/s00432-025-06264-0info:eu-repo/semantics/openAccessoai:dnet:idus________::3d7ab69d9e27e280a450acc1a7f098ca2026-06-17T12:51:07Z
dc.title.none.fl_str_mv Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
spellingShingle Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
Mangues Bafalluy, Irene
Non-small cell lung cáncer
Oral chemotherapy
Tyrosine kinase inhibitors
Anaplastic lymphoma kinase inhibitors
Adherence
Progression-free survival
title_short Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title_full Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title_fullStr Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title_full_unstemmed Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
title_sort Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study
dc.creator.none.fl_str_mv Mangues Bafalluy, Irene
Bernárdez Jiménez, Beatriz
Martínez Sesmero, José Manuel
Navarro Ruiz, Andrés
Martín Conde, María Teresa
Rubio Salvador, Ana Rosa
Rius Perera, Judith
Gilabert Sotoca, Marta
Domínguez López, Marta
Callejo Mellén, Ángel
author Mangues Bafalluy, Irene
author_facet Mangues Bafalluy, Irene
Bernárdez Jiménez, Beatriz
Martínez Sesmero, José Manuel
Navarro Ruiz, Andrés
Martín Conde, María Teresa
Rubio Salvador, Ana Rosa
Rius Perera, Judith
Gilabert Sotoca, Marta
Domínguez López, Marta
Callejo Mellén, Ángel
author_role author
author2 Bernárdez Jiménez, Beatriz
Martínez Sesmero, José Manuel
Navarro Ruiz, Andrés
Martín Conde, María Teresa
Rubio Salvador, Ana Rosa
Rius Perera, Judith
Gilabert Sotoca, Marta
Domínguez López, Marta
Callejo Mellén, Ángel
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Lenguajes y Sistemas Informáticos
TIC205: Ingeniería del Software Aplicada
dc.subject.none.fl_str_mv Non-small cell lung cáncer
Oral chemotherapy
Tyrosine kinase inhibitors
Anaplastic lymphoma kinase inhibitors
Adherence
Progression-free survival
topic Non-small cell lung cáncer
Oral chemotherapy
Tyrosine kinase inhibitors
Anaplastic lymphoma kinase inhibitors
Adherence
Progression-free survival
description Purpose We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Methods Observational, prospective, multicenter study performed by 6 hospital pharmacists in Spain. The primary outcome was the proportion of treatment adherence as evaluated by pill reconciliation during the 3-month active follow-up period. Those with an adherence > 80% were categorized as adherent. We performed multivariate Cox regression analyses to explore the factors associated with progression-free survival. Results From December 2019 to November 2022, we recruited 95 evaluable patients. Most of the patients received osimertinib (n = 45, 45.3%) or a first- or second-generation tyrosine kinase inhibitor (n = 23, 34.8%). Eighty-one patients showed greater than 80% adherence (85.3%, 95% CI 78.1% to 92.4%), as evaluated based on pill reconciliation; the mean (SD) adherence to OAT was 94.7% (11.4). According to the univariate analysis, the time to progression from study entry was significantly shorter among patients who were nonadherent than among those who were adherent (median 6.5 months vs. not reached, log-rank test p = 0.006; hazard ratio [HR] 2.619, 95% confidence interval [CI] 1.240–5.532). In the multivariate Cox regression analysis, nonadherence was the single factor associated with progression-free survival. Conclusion Consistent with previous evidence in this setting, our results suggest that adherence to oral antineoplastic treatment among patients with NSCLC is high. Whether this high rate of adherence translates to better clinical outcomes should be further evaluated in larger samples.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/186236
https://doi.org/10.1007/s00432-025-06264-0
url https://hdl.handle.net/11441/186236
https://doi.org/10.1007/s00432-025-06264-0
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Journal of Cancer Research and Clinical Oncology, 151 (8), 224-9 p..
https://link.springer.com/article/10.1007/s00432-025-06264-0
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417992206417920
score 15,811543

Similares en LA Referencia